EXEL — Exelixis, Inc.

Exelixis Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Approximately $599 million for Q4 2025, with cabozantinib franchise net product revenues of $546.6 million.
• CABOMETYX Revenues: $544.7 million in Q4 2025, with a full-year revenue of approximately $2.12 billion, reflecting a 17% increase from 2024.
• Gross to Net Deductions: 28.5% for Q4 2025, lower than previous quarters due to reduced 340B volume.
• Net Income: GAAP net income of approximately $244.5 million ($2.00 per share basic), and non-GAAP net income of $259.5 million ($0.97 per share basic).
• Cash Position: Approximately $1.66 billion in cash and marketable securities.
• Share Repurchases: $954 million of common stock repurchased in 2025, with $590 million remaining under the current buyback plan.

2. Strategic Updates and Business Highlights

• Focus on Oncology Franchises: Exelixis aims to build a multi-franchise business in solid tumor oncology, leveraging cabozantinib and zanzalutinib.
• CABOMETYX Performance: Continued leadership in renal cell carcinoma (RCC) and neuroendocrine tumors, with significant growth in both areas.
• Zanzalutinib Development: NDA accepted for ZanzaAteza combination in third-line colorectal cancer (CRC), with a PDUFA date set for December 2026.
• Pipeline Expansion: Seven ongoing pivotal trials for zanzalutinib and a robust early-stage pipeline of potential new oncology assets.

3. Forward Guidance and Outlook

• 2026 Financial Guidance: Expected gross to net for 2026 between 31-32%. The company anticipates continued growth in both CABOMETYX and ZANZA franchises.
• Market Strategy: Plans to expand the GI sales team to enhance market penetration for CABOMETYX and prepare for ZANZA's launch.

4. Bad News, Challenges, or Points of Concern

• Gross to Net Variability: Continued variability in 340B purchasing behavior may impact gross to net deductions in 2026.
• Regulatory Risks: Potential challenges in obtaining full approval for ZANZA, particularly regarding overall survival data from ongoing trials.
• Competitive Pressures: The oncology market remains highly competitive, with multiple therapies vying for market share, particularly in RCC and CRC.

5. Notable Q&A Insights

• ZANZA Launch Strategy: Management is optimistic about ZANZA's potential but remains cautious about predicting its impact until closer to the launch.
• Market Dynamics: There is significant unmet need in CRC, and the team is preparing for a fragmented market landscape.
• Future Trials: Discussions around ongoing trials and their potential impact on CABOMETYX's market share highlight the competitive landscape and the importance of demonstrating overall survival benefits.
• Share Repurchase Strategy: The company remains committed to repurchasing shares as long as they believe the stock is undervalued.

Overall, Exelixis reported strong financial performance in Q4 2025, with significant growth in its cabozantinib franchise and promising developments for its zanzalutinib pipeline. However, the company faces challenges related to regulatory approvals, market competition, and variability in gross to net deductions.